AbCellera Reports Positive Interim Phase 1 Data for ABCL635

What happened

AbCellera announced Q1 2026 results alongside positive interim Phase 1 data for ABCL635, its antibody for menopausal vasomotor symptoms, showing encouraging safety and early efficacy signals. While Q1 revenue remained minimal at roughly $9M and operating losses persisted near $75M, the data provide the first clinical validation of an internally developed asset. The ABCL635 results, though early, de-risk the pipeline and support the platform's ability to generate differentiated candidates with long-acting potential. However, the data are interim and limited; full Phase 1 results due mid-2026 will be critical to assess differentiation versus approved oral NK3 antagonists. Meanwhile, the cash runway remains above $600M, providing adequate funding through these milestones without near-term dilution.

Implication

The data incrementally support AbCellera's transition from a platform story to a clinical-stage pipeline, potentially narrowing the re-rating timeline. However, the stock still trades at a premium to its base case of $6, and the bar for ABCL635 is high given strong competition from oral agents. Long-term investors should use any strength to trim or await a better entry near the attractive entry of $3.50, as full data and partner milestones are needed to sustainably close the value gap.

Thesis delta

The positive interim Phase 1 data for ABCL635 modestly increase the probability of the bull case (from 25% to ~30%) and may bring the re-assessment window forward, but do not yet warrant upgrading from WAIT to BUY. The data must be validated in the full readout and show clear differentiation to justify a higher conviction rating.